Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral Neuropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    458 result(s) found for: Peripheral Neuropathy. Displaying page 7 of 23.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-024359-99 Sponsor Protocol Number: M11-891 Start Date*: Information not available in EudraCT
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain
    Medical condition: Diabetic Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004754-42 Sponsor Protocol Number: PP06490 Start Date*: 2019-01-22
    Sponsor Name:PledPharma AB
    Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5 FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in pa...
    Medical condition: Chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) FR (Completed) ES (Temporarily Halted) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004988-32 Sponsor Protocol Number: NL46993.078.13 Start Date*: 2014-01-22
    Sponsor Name:Erasmus MC
    Full Title: Rotterdam Observational Study in CIDP of Pharmacokinetics of Intravenous γ-globulin
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002692-16 Sponsor Protocol Number: APL-B-012-02 Start Date*: 2004-10-27
    Sponsor Name:PharmaMar SA unipersonal
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms.
    Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003121-29 Sponsor Protocol Number: D20180102 Start Date*: 2020-03-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes
    Medical condition: Vascular calcification and type 1 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002558-21 Sponsor Protocol Number: AT-001-2001 Start Date*: 2020-01-15
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in ...
    Medical condition: Diabetic Cardiomyopathy (DbCM) / Stage B Heart Failure (SBHF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000721-50 Sponsor Protocol Number: INCB54828-205 Start Date*: 2019-12-16
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment f...
    Medical condition: Male and female participants at least 18 years of age who have untreated metastatic or unresectable urothelial carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DE (Completed) FI (Prematurely Ended) FR (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001888-78 Sponsor Protocol Number: CC-4047-MM-010 Start Date*: 2012-10-22
    Sponsor Name:Celgene Corporation
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Medical condition: Refractory multiple myeloma (MM) or relapsed and refractory MM.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) SE (Completed) NL (Completed) DE (Completed) FI (Completed) AT (Completed) GR (Completed) GB (Completed) DK (Completed) IT (Completed) BE (Completed) IE (Completed) NO (Completed) SK (Completed) SI (Completed) EE (Prematurely Ended) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001653-27 Sponsor Protocol Number: MarsyasII Start Date*: 2019-12-20
    Sponsor Name:Aposcience AG
    Full Title: A randomized, placebo-controlled, double-blind study to evaluate safety and dose dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II)
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003957-14 Sponsor Protocol Number: KCP-330-023 Start Date*: 2017-03-14
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myelom...
    Medical condition: Relapsed or refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) AT (Completed) CZ (Completed) BE (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000257-39 Sponsor Protocol Number: PM60184-B-002-17 Start Date*: 2017-12-01
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Phase II, Open-label, Multicenter Study of PM060184 in Patients with Advanced Colorectal Cancer after Standard Treatment
    Medical condition: Advanced Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001003-20 Sponsor Protocol Number: AFM13-202 Start Date*: 2019-09-16
    Sponsor Name:Affimed GmbH
    Full Title: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides ...
    Medical condition: Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001999-40 Sponsor Protocol Number: EGF30001 Start Date*: 2004-11-25
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breas...
    Medical condition: Advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000635-15 Sponsor Protocol Number: 307970 Start Date*: 2005-09-07
    Sponsor Name:Schering AG
    Full Title: Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion o...
    Medical condition: Recurrent ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000597-53 Sponsor Protocol Number: 307972 Start Date*: 2005-12-08
    Sponsor Name:Schering AG
    Full Title: Phase II study to investigate the efficacy and safety of ZK 219477 as first-line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC)
    Medical condition: Extensive disease (ED) stage small cell lung cancer (SCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002758-35 Sponsor Protocol Number: IJB-AURA-ODN-004 Start Date*: 2018-05-16
    Sponsor Name:Insitut Jules Bordet
    Full Title: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers
    Medical condition: Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004196-37 Sponsor Protocol Number: PA02-124 1 RO1AT002146-01 Start Date*: 2006-09-22
    Sponsor Name:University of Birmingham, Research & Enterprise Services [...]
    1. University of Birmingham, Research & Enterprise Services
    2. Heart of England NHS Foundation Trust Birmingham Heartlands Hospital
    Full Title: Taurine and Painful Diabetic Neuropathy
    Medical condition: Diabetic painful peripheral neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004714-41 Sponsor Protocol Number: GBG69 Start Date*: 2012-05-18
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)
    Medical condition: Patients with primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018143-25 Sponsor Protocol Number: 2010 Start Date*: 2010-05-06
    Sponsor Name:Västra Götalandsregionen
    Full Title: An open label, historical control, study to assess the impact on bacteriological healing of Prednisolone in patients with neuroborreliosis-caused peripheral facial palsy receiving treatment with Do...
    Medical condition: Facialispares orsakad av CNS-infektion med Borrelia burgdorferi. (Neuroborrelios-orsakad facialispares)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052057 Neuroborreliosis LLT
    12.1 10016060 Facial palsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002288-84 Sponsor Protocol Number: RR3 Start Date*: 2019-08-12
    Sponsor Name:RenovoRx, Inc.
    Full Title: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable L...
    Medical condition: Locally advanced pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 00:49:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA